Sandostatin: profile and news

Ambrilia Announces First Quarter 2006 Results and Provides Update ...  May 10, 2006
Octreotide, Ambrilia's late-stage specialty generic for the treatment of acromegaly, is the equivalent of Novartis's Sandostatin ® LAR (long acting release ... - CCNMatthews (press release),

Ambrilia Announces First Quarter 2006 Results and Provides Update ...  May 10, 2006
Octreotide, Ambrilia's late-stage specialty generic for the treatment of acromegaly, is the equivalent of Novartis's Sandostatin® LAR (long acting release ... - Market Wire (press release)

(PZ) Novartis Delivers Strong Start to 2006 in First Quarter with ...  Apr 24, 2006
Sandostatin (USD 216 million, +1% lc) sales, for patients with acromegaly as well as treatment of patients with certain tumors, were slightly higher as strong ... - Houston Chronicle,

Pasireotide (SOM230) Shows Promise for Treating Acromegaly ...  May 2, 2006
..."Early data from phase 2 studies in metastatic carcinoid tumors resistant/refractory to Sandostatin LAR [octreotide injection], acromegaly, and Cushing's ... - DG News